🇺🇸 FDA
Patent

US 11958850

Heteroaryl compounds for kinase inhibition

granted A61PA61P1/04A61P1/18

Quick answer

US patent 11958850 (Heteroaryl compounds for kinase inhibition) held by Takeda Pharmaceutical Company Limited expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61P, A61P1/04, A61P1/18, A61P11/00, A61P15/00